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Recently, there has been a significant increase
in the prevalence of chronic liver disease in the
UK, and as a result, hospital admissions and
deaths due to liver disease have also increased.
The 2013 National Confidential Enquiry into
Patient Outcome and Death (NCEPOD) of
patients with alcohol-related liver disease
(ARLD) found that less than half the number of
patients who died from ARLD received ‘good
care’, and avoidable deaths were identified. In
order to improve the care of patients admitted
with ARLD, the NCEPOD report recommended
that a ‘toolkit’ for the acute management of
patients admitted with decompensated ARLD
be developed and made widely available. As a
result, we have developed a ‘care bundle’ for
patients admitted with decompensated cirrhosis
(of all aetiologies) to ensure that effective
evidence-based treatments are delivered within
the first 24 h. This care bundle provides a
checklist to ensure that all appropriate
investigations are undertaken when a patient
with decompensated cirrhosis presents and
provides clinicians with clear guidance on the
initial management of alcohol withdrawal,
infection, acute kidney injury, gastrointestinal
bleeding and encephalopathy. The first 24 h are
particularly important, as early intervention can
reduce mortality and shorten hospital stay, and
specialist gastroenterology/liver advice is not
always available during this period. This review
will discuss the care bundle and the evidence
base behind the treatment recommendations
made.
INTRODUCTION
Over the last 20 years, there has been a
significant increase in the prevalence of
chronic liver disease in the UK, with the
major causes being alcohol-related liver
disease (ARLD), hepatitis B and C and
obesity-related liver disease.1 There has
also been a substantial rise in hospital
admissions with complications of liver
disease, as well as a steady rise in liver-
related deaths in the UK.1 2 Liver disease
is now one of the major causes of prema-
ture death in the UK.3 Decompensated
cirrhosis and acute on chronic liver
failure are common causes for hospital
admission and are associated with a high
mortality rate.4 The 2013 National
Confidential Enquiry into Patient
Outcome and Death (NCEPOD) of
patients with ARLD ‘Measuring the
Units’ raised concerns about suboptimal
care of patients in hospital with compli-
cations of cirrhosis (due to ARLD),
which might have contributed to the rise
in liver-related mortality.5 The report
found that less than half (47%) the
patients who died from ARLD received
‘good care’, and avoidable deaths were
identified. It is likely that similar findings
would be observed for the management
of patients with cirrhosis of other
aetiologies.
In order to improve the care of patients
admitted with ARLD, the NCEPOD
report recommended that a ‘toolkit’ for
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the acute management of patients admitted with
decompensated ARLD be developed and made widely
available.5 As a result, we have developed a ‘care
bundle’ for patients admitted with decompensated cir-
rhosis (of all aetiologies) to ensure that effective
evidence-based treatments are delivered within the
first 24 h. The first 24 h are particularly important as
early intervention for presentations such as sepsis,
bleeding or renal dysfunction in patients with cirrhosis
can reduce mortality and shorten hospital stay, and
specialist gastroenterology/liver advice is not always
available during this period. This review will discuss
the care bundle and the evidence base behind the
treatment recommendations made. A copy for general
use is available at http://www.nescn.nhs.uk/wp-content/
uploads/2014/05/Cirrhosis-Care-Bundle.pdf and the
care bundle is shown in figure 1.
THE CARE BUNDLE
The care bundle is designed to be completed for all
patients presenting with decompensated cirrhosis and
should be commenced within 6 h of admission.
‘Decompensated cirrhosis’ is defined as an acute deteri-
oration in liver function in a patient with cirrhosis that
can manifest with the following: jaundice, increasing
ascites, hepatic encephalopathy, renal impairment/
hypovolaemia, gastrointestinal (GI) bleeding, or signs
of sepsis. Common precipitants for decompensated cir-
rhosis are shown in box 1. This care bundle is primarily
designed to provide recommendations on management
for the first 24 h only. After this period, it is expected
that specialist GI/liver input will be available to provide
guidance on further management.
BASELINE INVESTIGATIONS
On admission, it is vital that patients presenting with
decompensated cirrhosis have a full history and clin-
ical examination to look for the cause of deterioration
in liver function, infection or evidence of GI bleeding.
The National Early Warning Score should be recorded
and used to monitor the patient’s physiological
status.6 Blood tests should be taken to assess liver and
renal function, and this should include: full blood
count, urea and electrolytes (including calcium/phos-
phate/magnesium), liver function tests, coagulation
profile and glucose. As sepsis is a frequent cause of
admission, patients should also be screened for infec-
tion with clinical examination, urinalysis and urine
culture, chest X-ray, blood cultures and C-reactive
protein (CRP).5 7 Although not always a routine test,
serum CRP levels can help detect infection in cirrhotic
patients early.8 One study showed that a CRP level
greater than 10 mg/L was predictive of infections in
patients with cirrhosis (area under the receiver
Figure 1 The care bundle for decompensated cirrhosis.
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operator curve 0.93, sensitivity 84%, specificity 91%),
although the CRP can be elevated for other reasons,
such as alcoholic hepatitis.9
Additionally, an ascitic tap should be performed for
all patients who have clinically detectable ascites to
exclude spontaneous bacterial peritonitis (SBP).10
Coagulopathy is not a contraindication to this proced-
ure,5 and measures to correct coagulopathy are NOT
required. Ascitic fluid should be sent to the lab for
analysis of the fluid: polymorphonuclear (PMN) and
white cell count, microscopy and culture, protein and
albumin content.11 An abdominal ultrasound should
be requested and performed at the earliest opportun-
ity (unless an ultrasound has been conducted in the
last month), ideally within 24 h, and should include
an assessment of portal vein patency.
Alcohol
Seventy per cent of patients in the UK, admitted with
cirrhosis, have alcohol as the major aetiological factor.12
The patient’s current and previous alcohol history (in
units/day: box 2), time of last drink and any symptoms
of alcohol withdrawal should be documented.5 For
patients with current excessive alcohol consumption,
parenteral thiamine and other B vitamins (Pabrinex:
two pairs of vials three times daily for 3 days) should be
given to treat thiamine deficiency and reduce the risk of
Wernicke’s encephalopathy or Korsakoff ’s syndrome.13
Patients who have symptoms of alcohol withdrawal or
are at high risk of alcohol withdrawal, seizures or delir-
ium tremens should be assessed with a validated tool for
alcohol withdrawal, such as the revised Clinical Institute
Withdrawal Assessment–Alcohol (CIWA-Ar) scale, and
be treated with a symptom-triggered regimen of
benzodiazepines.13 14
Infections
Patients with cirrhosis have impaired defence against
bacteria due to immune dysfunction, and as a result,
bacterial infections are one of the most frequent
reasons for admission and are associated with a high
mortality rate.8 15 16 A careful assessment for infec-
tion is critical in all patients admitted with decompen-
sated cirrhosis, as prompt treatment with antibiotics
improves prognosis.17 The most common infections
in cirrhotics are SBP, followed by urinary tract infec-
tions and pneumonia,8 18 and Gram-negative bacilli,
such as Escherichia coli, are the most frequently
encountered pathogens.19 There has been a recent
increase in the prevalence of infections with multidrug
resistant bacteria in patients with cirrhosis, which
emphasises the importance of taking the appropriate
samples for culture and sensitivity, so patients can
have their antibiotics modified accordingly.20
Importantly, patients with cirrhosis do not always
display typical signs of infection, such as pyrexia or
rise in CRP, so clinicians must have a high index of
suspicion for infection. Once suspected clinically,
infection should be treated promptly with broad spec-
trum antibiotics as per hospital protocol.
SBP is defined as infection of the ascitic fluid in the
absence of a secondary cause, such as intestinal per-
foration, and occurs in approximately 10% of hospita-
lised patients with cirrhosis.16 18 Although abdominal
pain and fever are commonly seen in patients with
SBP, symptoms are frequently absent.21 It is, therefore,
recommended that all patients presenting with ascites
have a diagnostic ascitic tap to exclude SBP on admis-
sion to hospital, or if there is deterioration in their
clinical status.5 10 11 Diagnosis of SBP is made when
the absolute number of PMN cells is >250/mm3 of
ascitic fluid.22 Upon diagnosis, SBP should be empiric-
ally treated with broad spectrum antibiotics, such as
third-generation cephalosporin (cefotaxime or cef-
triaxone), co-amoxiclav or ciprofloxacin, according to
hospital policy, with modifications made in light of
subsequent culture results.8 10 11 Patients with SBP are
at high risk of developing hepatorenal syndrome
(HRS) and should have intravenous albumin adminis-
tered to prevent worsening of renal function.10
Studies have shown that intravenous albumin 1.5 g/kg
Box 1 Definition of decompensated cirrhosis and
common precipitants
Decompensated cirrhosis=deterioration in liver function





▸ Signs of sepsis/hypovolaemia
Common precipitants of decompensated cirrhosis:
▸ Gastrointestinal bleeding (variceal and non-variceal)
▸ Infection/sepsis (spontaneous bacterial peritonitis,
urine, chest, cholangitis, etc)
▸ Alcoholic hepatitis
▸ Acute portal vein thrombosis
▸ Development of hepatocellular carcinoma
▸ Drugs (alcohol, opiates, NSAIDs, etc)
▸ Ischaemic liver injury (sepsis or hypotension)
▸ Dehydration
▸ Constipation (encephalopathy)
Box 2 Definition of units of alcohol
▸ One unit of alcohol=10 mL of alcohol or 8 g of alcohol
▸ Example: a 500 mL can of 5% Beer=25 mL of
alcohol=2.5 units of alcohol
▸ The maximum recommended weekly alcohol con-
sumption is 21 units for men and 14 units for women.
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at diagnosis and 1 g/kg at 72 h reduces the incidence
of HRS from 30% to 10% and reduces mortality
from 29% to 10%.23
Acute kidney injury and/or hyponatraemia
Acute kidney injury (AKI) is estimated to occur in
approximately 20% of hospitalised patients with cir-
rhosis, and is associated with a poor prognosis.24 25
Several definitions of AKI exist, but the National
Institute of Health and Care Excellence (NICE)
recommends the use of the modified RIFLE (Risk
Injury Failure Loss and End stage renal disease) cri-
teria that were devised by the Acute Kidney Injury
Network to detect subjects at risk of AKI.26 27 AKI is
defined if any of the following criteria are met: (1) an
absolute rise in serum creatinine of ≥26 mmol/L
within 48 h; (2) a ≥50% increase in serum creatinine
known or presumed to have occurred in the last
7 days; (3) a fall in urine output to <0.5 mL/kg/h for
6 h.27 It should be noted that patients with cirrhosis
frequently have low baseline creatinine levels, as many
have reduced muscle bulk and malnutrition.
Therefore, some patients with creatinine levels within
the normal range can have a significantly reduced
glomerular filtration rate.
AKI in patients with cirrhosis is commonly multifac-
torial, but prerenal AKI is most common (45%),
followed by acute tubular necrosis and glomeruloneph-
ritis (32%), HRS (23%) and rarely postrenal (<1%).25
It is important to identify the cause of AKI, as the
underlying cause has implications on prognosis. Type 1
HRS (acute) carries a particularly poor prognosis with
mortality rates approaching 100% without treatment.
HRS is a diagnosis of exclusion, and current diagnostic
criteria are shown in box 3.28 It is important to note
that before a diagnosis of HRS can be made patients
need to have their diuretics and nephrotoxic medica-
tions suspended and be volume expanded with
albumin, so a diagnosis of HRS can usually not be
made within the first 24 h. If HRS is subsequently
diagnosed, patients should be treated with intravenous
albumin and terlipressin, as this has been shown to
reduce mortality in patients with HRS.29
Early intervention in patients with AKI can prevent
further deterioration in renal function leading to renal
failure. Initial management of AKI should include sus-
pension of all diuretics and nephrotoxic drugs.30 31
Patients should be fluid-resuscitated with 0.9% saline
or 5% albumin, giving boluses of 250 mL with
regular volume status reassessment aiming to achieve
euvolaemia with a urine output of >0.5 mL/kg/h
based on dry weight.32 33 Accurate fluid balance mon-
itoring and daily weight charts should be commenced.
Usually 1–2 L of intravenous fluid will correct most
losses and render the patient euvolaemic. If after 6 h
the target urine output is not achieved, or the
patient’s clinical parameters are worsening, then escal-
ation to high-dependency care for more invasive mon-
itoring, inotropic support or renal support should be
considered.
Hyponatraemia is common in patients with decom-
pensated cirrhosis and can be caused by multiple factors
including: hormonal dysregulation of salt and water
balance in response to portal hypertension, dehydration,
treatment with diuretics, infections and excessive use of
hypotonic fluids, such as 5% dextrose.10 Patients with
serum sodium levels <125 mmol/L are at risk of sei-
zures. A careful history, clinical examination, medication
review and review of other biochemistry are essential to
determine the cause of hyponatraemia. Assessment of
the patient’s volume status is fundamental, and subjects
who are hypovolaemic should be fluid-resuscitated.
Patients with hypervolaemic hyponatraemia should be
treated with fluid restriction. However, it should be
noted that some patients with significant ascites, periph-
eral oedema and low serum albumin levels who appear
hypervolaemic are actually intravascularly deplete, and
treatment with intravenous albumin can correct the
hyponatraemia.34 Correction of hyponatraemia should
be slow (<10 mmol/L increase per 24 h), as rapid
changes in serum sodium can precipitate osmotic
demyelination syndrome.
GI bleeding
Bleeding oesophageal and gastric varices are another
important complication of cirrhosis with a high mortal-
ity rate. A recent UK-wide audit showed the overall
30-days mortality was 15% for patients with acute vari-
ceal bleeding, with higher mortality rates in subjects
with more advanced cirrhosis.35 Airway protection is
vital, particularly in patients with encephalopathy or
massive GI bleeding to reduce the risk of aspiration.36
In patients with known varices or portal hypertension,
upper GI bleeding should be regarded as variceal until
proven otherwise, although a significant proportion will
have non-variceal bleeding. Patients should be
fluid-resuscitated according to pulse and blood pressure,
aiming for a mean arterial pressure of >65 mm Hg.7
Box 3 Diagnostic criteria for hepatorenal syndrome28
▸ Cirrhosis with ascites
▸ Serum creatinine >133 mmol/L
▸ No improvement of serum creatinine to <133 mmol/L
after at least 2 days with diuretic withdrawal and
volume expansion with albumin (1 g/kg up to a
maximum of 100 g/day)
▸ Absence of shock
▸ No current treatment with nephrotoxic drugs
▸ Absence of parenchymal kidney disease as indicated
by proteinuria (>500 mg/day) or microhaematuria
(>50 red blood cells per high-power field) and/or a
normal renal ultrasonography
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Transfusion of red blood cells is indicated when the
haemoglobin (Hb) falls below 7 g/dL37 aiming for an
Hb of 8 g/dL. It has been recently shown that a restrict-
ive blood transfusion strategy (transfuse when Hb <7 g/
dL) had lower mortality compared with a liberal strategy
of transfusion (transfuse when Hb <9 g/dL) in patients
with cirrhosis and with GI bleeding.38 The liberal strat-
egy also increased the portal pressure over 5 days, thus
increasing the potential for rebleeding.38 Coagulation
abnormalities are common in patients with cirrhosis and
may require correction in patients with active bleeding.
Although not evaluated in randomised controlled trials,
correction of blood clotting abnormalities is recom-
mended by NICE when the international normalised
ratio (INR) is >1.5 (fresh frozen plasma), platelet count
is <50×109/L (platelets) or fibrinogen <1.0 g/L (cryo-
precipitate).39 Consider giving intravenous vitamin K in
patients with cirrhosis and with a prolonged prothrom-
bin time, as vitamin K deficiency is common due to mal-
nutrition and chronic cholestasis.
In patients with suspected variceal bleeding, terli-
pressin (2 mg four times daily) should be administered
intravenously as soon as possible to control bleed-
ing.39 Terlipressin is a vasopressin analogue that
reduces portal pressure by inducing splanchnic vaso-
constriction and has been shown to improve control
of bleeding, as well as reduce all-cause mortality in
patients with cirrhosis and with variceal bleeding.40 41
Significant adverse events with terlipressin are uncom-
mon, but because of its vasoconstrictor activity it
should be used with caution in patients with known
or suspected ischaemic heart disease or peripheral vas-
cular disease and those older than 65 years of age,
making a baseline ECG mandatory. For patients who
have a contraindication to terlipressin (or if terlipres-
sin is unavailable), a continuous intravenous infusion
of octreotide is an alternative.37 40 Once patients have
been adequately resuscitated, endoscopy should be
performed at the earliest opportunity (ideally within
6–12 h, but not more than 24 h) to determine the
cause of bleeding and perform endotherapy as indi-
cated.7 39 Bacterial infections, particularly SBP, are
common in patients with cirrhosis in the first 7 days
post-GI bleeding, occurring in 25%–65% of
patients.10 Prophylaxis with antibiotics post-GI bleed
have been shown to reduce short-term mortality, as
well as the risk of rebleeding, septicaemia and
SBP.42 43 It is, therefore, recommended that patients
with cirrhosis and GI bleeding (variceal and non-
variceal) receive prophylaxis with a broad spectrum
antibiotic, such as cefotaxime or co-amoxiclav, as per
hospital protocol, as soon as possible.8 39 Patients
with advanced cirrhosis (any two of the following:
ascites, severe malnutrition, encephalopathy or jaun-
dice) are at highest risk of developing infection and
should receive the antibiotics intravenously.44
Importantly, there appears to be no increase in the
incidence of Clostridium difficile infection in patients
receiving antibiotic prophylaxis for variceal bleeding
compared with the hospital medical population.45
Encephalopathy (delirium)
Encephalopathy is another common complication in
patients with cirrhosis.46 A careful assessment of the
cause of encephalopathy should be undertaken
looking for causes such as infection, electrolyte dis-
turbance, occult bleeding, constipation or sedative
drugs.7 For patients with grade 4 encephalopathy
(coma) consider orotracheal intubation to reduce the
risk of developing aspiration pneumonia. In conscious
patients, oral lactulose (20 mL–30 mL four times per
day) should be administered aiming for 2 soft stools
per day. For patients with a reduced conscious level,
phosphate enemas or lactulose administered by naso-
gastric tube should be considered. Consider a CT
head examination in patients where the confusion is
unexplained to exclude intracranial pathology, such as
subdural haematoma.
Other considerations
In the recent UK audit of blood component use in cir-
rhosis, thrombotic events occurred in 3% of patients.12
Thromboprophylaxis with low-dose, low molecular
weight heparin (LMWH), is therefore recommended to
reduce the risk of thrombosis, unless the patient is bleed-
ing or has a platelet count less than 50×109/L.12 Recent
evidence suggests that even with apparent abnormalities
on blood testing suggestive of a hypocoagulable state
(prolonged prothrombin time), patients with cirrhosis
typically have normal clot-forming capacity provided
the platelet count is >50×109/L, and some patients
with advanced cirrhosis are actually hypercoagulable.47
Changes in the balance of the hepatic production of
procoagulant and anticoagulant blood clotting factors in
cirrhosis are believed to be responsible for this phenom-
enon.48 Although thromboprophylaxis with LMWH
has not been specifically trialled in hospitalised patients
with decompensated cirrhosis to prevent thrombo-
embolism, a previous study demonstrated that the
administration of enoxaparin 4000 m/day for 48 weeks
reduced the risk of portal vein thrombosis, liver decom-
pensation and mortality, and no haemorrhagic side
effects were seen.49
Malnutrition and nutritional deficiency are
common in hospitalised patients with cirrhosis.50
Moreover, reduced calorific intake in hospitalised
patients with cirrhosis is an independent risk factor
for short-term mortality.50 Therefore, a nutritional
assessment should be performed early in the admis-
sion and, if indicated, nutritional supplementation
(oral or nasogastric) should be prescribed. Close mon-
itoring of electrolytes (phosphate, magnesium, potas-
sium and calcium) is mandatory as refeeding
syndrome is common. Low electrolyte levels should
be corrected promptly.
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Patients with decompensated cirrhosis should be
reviewed by a consultant at the earliest opportunity,
ideally within 6 h, but not more than 12 h, as they typic-
ally have multiple medical needs and have a high mor-
tality.5 Additionally, these patients should be reviewed
by a specialist gastroenterologist/hepatologist, ideally
within 24 h, but not more than 72 h after admission to
hospital.5 In order to facilitate this, it is recommended
that every acute hospital should have a liver lead or
‘champion’ to try and improve care for patients with
liver disease and improve pathways of care.3
Escalation to a higher level of care needs to be consid-
ered in all patients not responding to treatment when
reviewed after 6 h, particularly in patients with WHO
performance status 0–1 prior to the recent illness and
those with first presentation.5 A Consultant-to-
Consultant discussion is recommended. Prognostic
scores that are commonly used in intensive care units
(ICU), such as the Sepsis-Related Organ Failure
Assessment score, assessed at baseline and at 48 h can be
effective in predicting mortality in patients with cirrho-
sis who are admitted to ICU. These scores could be used
to help identify patients who would benefit from ICU
care, as well as identify those where prolonged ICU
treatment would be futile.51 52
CONCLUSIONS
The recent NCEPOD report on ARLD highlighted
that the management of some patients with decom-
pensated cirrhosis in the UK was suboptimal. In order
to address these concerns, we have developed a ‘care
bundle’ for patients admitted with decompensated cir-
rhosis, to ensure the appropriate initial investigations
and interventions are conducted at an early stage
when specialist advice may not be available. It is
hoped that this care bundle will help improve the care
of patients admitted to hospital with decompensated
cirrhosis across the UK, but this will need to be for-
mally evaluated. This care bundle could also be a
focus for audit, nationally regarding the management
of patients with decompensated cirrhosis.
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